EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Knowledge Gain Through High Parallel Bioprocess Setups
Product Life Cycle Manager, Eppendorf AG
Sebastian Kleebank studied Bioengineering at the University of Applied Sciences in Juelich followed by his PhD at the RWTH Aachen Institute for Molecular Biotechnology In his actual position as a Product Life Cycle Manager at Eppendorf AG Business Unit Bioprocess he is responsible for the smallscale product portfolio During his years in the bioprocess industry he gained a lot of experience in sma...
Articles
Harnessing Artificial Intelligence
The incorporation of Artificial Intelligence AI in the discovery and development of drugs represents a significant step towards transforming drug delivery systems
Research Insights
Zika Virus Replicons For Drug Discovery
Abstract The current epidemic of Zika virus ZIKV has underscored the urgency to establish experimental systems for studying viral replication and pathogenesis and countermeasure development Here we report two ZIKV replicon systems a luciferase replicon that can differentiate between viral translation and RNA synthesis and a stable luciferase replicon carr
Case Studies
Evaluation of A Sequencing Batch Reactor Sewage Treatment Rig For Investigating The Fate of Radioactively Labelled Pharmaceuticals: A Case Study of Propranolol
Abstract Pharmaceuticals are frequently detected in the aquatic environment and have potentially damaging effects Effluents from sewage treatment plants STPs are major sources of these substances The use of sequencing batch reactor SBR STPs involving cycling between aerobic and anoxic conditions to promote nitrification and denitrification is increasin
Techno Trends
AstraZeneca Introduces A Breakthrough Therapy-Tagrisso
AstraZeneca introduced Tagrisso osimertinib a breakthrough therapy for the adjuvant treatment of patients with earlystage IB II and IIIA Epidermal Growth Factor Receptormutated EGFRm NonSmall Cell Lung Cancer NSCLC
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Why Tackling Antibiotic Tolerance Is Crucial to Combating AMR and Saving Our Existing Antibiotics
Entrusted with the mandate of augmenting and monetising the company’s intellectual property wealth and driving key tactical initiatives, Saransh Chaudhary joined Venus Remedies in 2016 as Strategic Board Advisor after completing his undergraduate degree in Accounting & Finance from Cass Business School, London. Two years later, he assumed charge as President of the company’s Global Critical Care division and CEO of Venus Medicine Research Centre (VMRC), its R&D wing. In these roles, he translates priorities into actionable strategies.
Moving from Code to Consequence
Dr. Sanjesh Kumar is an Assistant Professor at Chandigarh University Uttar Pradesh with a Ph.D. in Pharmacology. An award-winning academician specialized in neurodegenerative disorders and advanced drug delivery, he has authored over 45 high-impact publications and holds multiple patents, seamlessly bridging the gap between clinical research and classroom education.
Dr. Disha Marwaha earned a Ph.D. in Biological Sciences from the CSIR-Central Drug Research Institute (CSIR-CDRI) in 2024 and currently serves as an Assistant Professor at Chandigarh University Uttar Pradesh. Her research encompasses nanomedicine, pharmacokinetics, formulation development, and targeted drug delivery systems. She has authored more than 22 articles in peer-reviewed international journals.
Reshaping the Clinical Trial Model
Anna Hayes is a senior data management leader (At Veramed) with nearly 20 years of experience in clinical research. She specializes in biometrics strategy, innovation, and operational excellence, driving smarter oversight and data-driven trial execution. Anna is passionate about integrating people, processes, and technology to future-proof clinical trials and elevate data quality.
Schedule M guideline: Revision and its nationwide implementation
Dr. M. Aamir Mirza is working as an Assistant Professor in the Department of Pharmaceutics, Jamia Hamdard, an NIRF Rank 1 institute and a NAAC ‘A+” grade deemed to be University. He has a multifaceted career portfolio adorned with both industry and academic accomplishments. During his industry stay he became a seasoned scientist and dealt with challenging NCE/NDA development. He is on advisory boards of some international research-based companies of India, New Zealand and Europe. Academics and Research being close to his heart, he has published more than 110 manuscripts in the journals of international repute and has been granted 02 Indian patent and filed for 04. He has contributed several chapters in books published by reputed authors like Elsevier and Bentham. He is amongst the very few scientists globally who has an expertise in Humic substances research. A well-travelled scientist; he has delivered scientific addresses in countries like USA, Austria, Japan, Netherlands, Turkey, Estonia, Spain and Russia. He has been Elite Fellow at University of Malaya (Malaysia) for the last 5 years where he takes classes on the topics related to industrial pharmacy.
Computational Approach towards Designing Potent Inhibitors for Tuberculosis
Soumyadip Das received a BSc degree from University of Calcutta, India, in 2017 and a MSc degree from Vellore Institute of Technology, Vellore, India, in 2019. He is currently pursuing his PhD degree from Vellore Institute of Technology, Vellore, India, under the supervision of Dr. Kaushik Chanda. His research interest includes diversity-oriented synthesis, anticancer drug design, and nanocatalysis.
Balamurali MM, was awarded the Master’s degree in Chemistry, by Madurai Kamaraj University, Tamil Nadu, India in 1999. He persuaded his doctoral research in Photophysical Chemistry at Indian Institute of Technology Kanpur, under the supervision of Prof. Sneh Kumar Dogra. In 2005, he was awarded the CSIR research associate fellowship and continued his postdoctoral research in Prof. Raghavan Varadarajan’s group at Indian Institute of Science Bangalore.
Kaushik Chanda, obtained his MSc in Organic Chemistry from Gauhati University, Assam India in 2001. Subsequently worked as a Senior Research Fellow in ICAR-NATP funded project in St Anthonys College, Shillong, India from 2002-2005. In 2006, he moved to Taiwan for pursuing PhD in Applied Chemistry from National Chiao Tung University under the guidance of Prof Chung Ming Sun on a topic of Combinatorial Chemistry.
press releasesRead more...
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Telix and Ekalia a joint venture between IBA Ion Beam Applications SA EURONEXT and Framatome today announced a collaboration to advance scalable United States US production of astatine At an alphaemitting radioisotope being investigated for targeted alpha therapy
HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases
HistoIndex a pioneer in AIdriven digital pathology for fibrotic diseases and the Agency for Science Technology and Research ASTAR Singapores lead public sector RD agency have signed a Memorandum of Understanding MoU to collaborate on the preclinical evaluation
Cotecna Group Acquires Energon Labs
Cotecna a leading provider of Testing Inspection and Certification TIC services today announced the acquisition of Energon Labs a cGMPcompliant USFDAinspected ISO and ISO certified analytical testing laboratory based in Hyderabad India
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...
Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus
Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...
EventsRead more...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
LATEST NEWSRead more...
UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis
UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies
Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ
Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals
Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours
Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...
Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases
Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...
Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors
Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...